Nonprescription acne vulgaris treatments: Their role in our treatment armamentarium-An international panel discussion.
acne in adult women
acne vulgaris
adjunctive treatment
dermocosmetics
monotherapy
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
01
04
2020
revised:
12
04
2020
accepted:
14
05
2020
pubmed:
20
5
2020
medline:
15
5
2021
entrez:
20
5
2020
Statut:
ppublish
Résumé
Acne vulgaris (acne), a common inflammatory skin disorder, has its peak incidence between 14 and 19 years of age, with girls frequently developing acne earlier than boys. Over recent years, persistent acne is becoming more prevalent in adult women. This review and panel discussion addresses challenges in acne management, particularly in adult women. The role which nonprescription acne treatment can play is explored when used as monotherapy or as an adjunctive treatment for acne of all severity. The best available evidence on nonprescription acne treatment was coupled with the opinion of an international expert panel of dermatologists to adopt statements and recommendations discussed in this review. All severity of acne has a significant burden on patients. Addressing environmental factors that are important for the individual with acne may help to educate, prevent, effectively manage, and maintain acne, as per the panel. They agreed that the adult female acne population has unique needs because of their aging skin and social environment. Nonprescription acne treatment products may help to balance the efficacy and tolerability of prescription acne treatment. Currently, there are no specific guidelines for how to use nonprescription acne treatment products in these patients. The panel agreed that guidelines including nonprescription acne treatment either as monotherapy for mild acne or in combination with prescription treatments for more severe acne would address a significant unmet need.
Sections du résumé
BACKGROUND
BACKGROUND
Acne vulgaris (acne), a common inflammatory skin disorder, has its peak incidence between 14 and 19 years of age, with girls frequently developing acne earlier than boys. Over recent years, persistent acne is becoming more prevalent in adult women.
OBJECTIVES
OBJECTIVE
This review and panel discussion addresses challenges in acne management, particularly in adult women. The role which nonprescription acne treatment can play is explored when used as monotherapy or as an adjunctive treatment for acne of all severity.
METHODS
METHODS
The best available evidence on nonprescription acne treatment was coupled with the opinion of an international expert panel of dermatologists to adopt statements and recommendations discussed in this review.
RESULTS
RESULTS
All severity of acne has a significant burden on patients. Addressing environmental factors that are important for the individual with acne may help to educate, prevent, effectively manage, and maintain acne, as per the panel. They agreed that the adult female acne population has unique needs because of their aging skin and social environment. Nonprescription acne treatment products may help to balance the efficacy and tolerability of prescription acne treatment. Currently, there are no specific guidelines for how to use nonprescription acne treatment products in these patients.
CONCLUSION
CONCLUSIONS
The panel agreed that guidelines including nonprescription acne treatment either as monotherapy for mild acne or in combination with prescription treatments for more severe acne would address a significant unmet need.
Identifiants
pubmed: 32426933
doi: 10.1111/jocd.13497
pmc: PMC7496538
doi:
Substances chimiques
Dermatologic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2201-2211Subventions
Organisme : Vichy Laboratoires, France
Informations de copyright
© 2020 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.
Références
J Dermatol Sci. 2017 Mar;85(3):152-161
pubmed: 27720464
Dermatoendocrinol. 2017 Oct 13;9(1):e1361572
pubmed: 29484094
Br J Dermatol. 2016 Jun;174(6):1299-307
pubmed: 26799159
J Eur Acad Dermatol Venereol. 2016 May;30(5):824-8
pubmed: 26642798
Health Promot Perspect. 2017 Mar 05;7(2):106-108
pubmed: 28326292
J Eur Acad Dermatol Venereol. 2018 Jun;32 Suppl 2:5-14
pubmed: 29894579
J Invest Dermatol. 2011 Feb;131(2):363-70
pubmed: 20844551
J Eur Acad Dermatol Venereol. 2016 Jun;30(6):926-35
pubmed: 26916232
J Clin Aesthet Dermatol. 2017 Sep;10(9):12-23
pubmed: 29344322
Dermatology. 2019;235(4):287-294
pubmed: 31112983
Int J Dermatol. 2016 Nov;55(11):1196-1204
pubmed: 27421121
J Drugs Dermatol. 2016 Jan;15(1 Suppl 1):s11-6
pubmed: 26741391
J Cutan Aesthet Surg. 2013 Oct;6(4):204-8
pubmed: 24470716
J Am Acad Dermatol. 2018 Feb;78(2 Suppl 1):S1-S23.e1
pubmed: 29127053
Int J Cosmet Sci. 2016 Jun;38(3):217-23
pubmed: 26291783
J Invest Dermatol. 2014 Jun;134(6):1527-1534
pubmed: 24166134
J Drugs Dermatol. 2012 Sep;11(9):1104-7
pubmed: 23135655
J Cutan Aesthet Surg. 2015 Apr-Jun;8(2):88-91
pubmed: 26157307
Lancet. 2012 Dec 15;380(9859):2163-96
pubmed: 23245607
J Clin Aesthet Dermatol. 2014 Mar;7(3):13-7
pubmed: 24688621
J Eur Acad Dermatol Venereol. 2017 Sep;31 Suppl 6:3-18
pubmed: 28805934
BMJ. 2010 Nov 11;341:c5812
pubmed: 21071484
J Drugs Dermatol. 2013 Apr;12(4):434-7
pubmed: 23652891
J Cosmet Dermatol. 2020 Sep;19(9):2201-2211
pubmed: 32426933
CMAJ. 2010 Dec 14;182(18):E839-42
pubmed: 20603348
Eur J Dermatol. 2018 Aug 1;28(4):502-508
pubmed: 30187864
J Eur Acad Dermatol Venereol. 2017 Sep;31 Suppl 5:8-12
pubmed: 28805938
J Cosmet Dermatol. 2019 Jun;18(3):815-820
pubmed: 30964240
J Clin Aesthet Dermatol. 2012 May;5(5):32-40
pubmed: 22808307
J Invest Dermatol. 2016 Jan;136(1):127-35
pubmed: 26763432
Am J Clin Dermatol. 2018 Aug;19(4):459-477
pubmed: 29744784
J Dermatol. 2016 Jul;43(7):826-8
pubmed: 26813513
Br J Dermatol. 2013 Mar;168(3):474-85
pubmed: 23210645
J Am Acad Dermatol. 2013 Jun;68(6):1022-9
pubmed: 23332517
J Dermatolog Treat. 2019 Sep;30(6):578-581
pubmed: 30426810
J Dermatol. 2015 Feb;42(2):181-8
pubmed: 25483138
J Clin Aesthet Dermatol. 2014 Mar;7(3):18-26
pubmed: 24688622
BMC Dermatol. 2015 Sep 11;15:17
pubmed: 26361978
Acta Derm Venereol. 2016 Feb;96(2):283-4
pubmed: 26338511
J Clin Aesthet Dermatol. 2013 Feb;6(2):18-24
pubmed: 23441236
Br J Dermatol. 2015 Jul;172 Suppl 1:3-12
pubmed: 25597339
Clin Cosmet Investig Dermatol. 2018 Feb 01;11:59-69
pubmed: 29440921
J Womens Health (Larchmt). 2012 Feb;21(2):223-30
pubmed: 22171979
Ann Dermatol Venereol. 2012 Dec;139 Suppl 4:S148-52
pubmed: 23522630
J Eur Acad Dermatol Venereol. 2020 May;34(5):1057-1064
pubmed: 31785166
J Drugs Dermatol. 2013 Mar;12(3):266-9
pubmed: 23545907
Int J Cosmet Sci. 2015 Jun;37(3):329-38
pubmed: 25655908
J Eur Acad Dermatol Venereol. 2015 Jun;29 Suppl 5:1-7
pubmed: 26059819
J Eur Acad Dermatol Venereol. 2016 Aug;30(8):1261-8
pubmed: 27514932